IDH1 and glioma: In summary, Rab27a expression was significantly associated with grade progression and poor prognosis in all glioma grades, including mesenchymal and G3 subtype and wild-type IDH1, suggesting Rab27a as a novel biomarker with potentially important therapeutic implications.